Back

Three decades of lipid-lowering therapy in type 2 diabetic patients with angiographically proven stable coronary artery disease

2 September 2024 (10:00 - 10:50)
Organised by: Logo
Congress Presentation Part of: Medical and percutaneous treatment of coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speakers

Photo
Professor Heinz Drexel

Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch (Austria)

Photo
Doctor Arthur Mader

VIVIT Institute, Feldkirch (Austria)

7 More presentations in this session

Presentation thumbnail
Placebo-controlled efficacy of 17 anti-anginal drugs and percutaneous coronary intervention for first-line treatment of stable angina: systematic review & meta-analysis of 5153 patients from 53 trials
Doctor A. Kaura (London, GB)
Abstract Slides Video
Presentation thumbnail
Persistent angina following revascularization for chronic coronary syndromes: a systematic review and meta-analysis of randomized controlled trials
Doctor A. Singh (Los Angeles, US)
Abstract Slides Video
Presentation thumbnail
Comparative meta-analysis: drug-coated balloon versus drug-coated stent - a comprehensive evaluation of efficacy and safety in stentless percutaneous coronary intervention for coronary artery disease
Slides Video
Presentation thumbnail
Effect of primary pci in asymptomatic stemi patients presenting 12 to 48 hours of symptom onset, on myocardial viability assessed by spect tc 99m sestamibi scan epitome99
Doctor M. Pandit (Bangalore, India, IN)
Abstract Slides Video
Presentation thumbnail
Impact of symptom-to-balloon time on long-term prognosis: a 3-year follow-up study in non-st-segment elevation myocardial infarction patients with complex lesions
Professor Y. Kim (Chuncheon, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Medical and percutaneous treatment of coronary artery disease

The Event

Event poster

ESC Congress 2024

2 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Session
Changing face of lipid-lowering therapy
thumbnail
Congress Presentation
Temporal trends in lipid-lowering therapy utilization among ASCVD patients: a large-scale database analysis
thumbnail
Congress Presentation
A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources